<DOC>
	<DOCNO>NCT03091868</DOCNO>
	<brief_summary>To investigate effect rise oral single-doses BIA 6-512 ( 25 mg , 50 mg , 100 mg 200 mg ) levodopa pharmacokinetics administer combination single-dose immediate release levodopa/carbidopa 100/25 mg ( Sinemet® 100/25 ) single-dose Sinemet® 100/25 plus single-dose entacapone ( Comtan® ) 200 mg ass tolerability safety rise single oral dos BIA 6-512 administered combination single-dose Sinemet® 100/25 single-dose Sinemet® 100/25 plus single-dose Comtan® 200 mg .</brief_summary>
	<brief_title>Pharmacokinetics Rising Single-doses BIA 6-512 Their Effect Levodopa Pharmacokinetics</brief_title>
	<detailed_description>Single centre , double-blind , randomise , placebo-controlled study four sequential group healthy subject . Eligible subject admit UFH day prior receive first study medication . On morning first dosing day ( Day 1 ) , subject receive BIA 6-512/Placebo concomitantly Sinemet® 100/25 ; morning second dosing day ( Day 2 ) , subject receive BIA 6-512/Placebo concomitantly Sinemet® 100/25 Comtan® 200 mg. Products administer fasting condition ( least 8 hour ) . Subjects remain confined UFH admission ( Day 0 ) least 24 h post last dose ( Day 3 ) ; , discharge return follow-up visit .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Subjects clinical laboratory test clinically acceptable screen admission . Subjects negative test HBsAg , antiHCVAb antiHIV1 antiHIV2 Ab screening . Subjects negative screen alcohol drug abuse screen admission . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She sterile , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative urine pregnancy test screen admission . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 21 unit alcohol week . Subjects significant infection know inflammatory process screen admission . Subjects acute gastrointestinal symptom time screen admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use prescription overthecounter medication within 2 week admission . Subjects use investigational drug participate clinical trial within 3 month prior screen . Subjects donate received blood blood product within 3 month prior screen . Subjects vegetarian , vegan medical dietary restriction . Subjects communicate reliably investigator . Subjects unlikely cooperate requirement study . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>